Richard C. Mulligan

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Richard C. Mulligan, Ph.D., (born 1954) is the Mallinckrodt Professor of Genetics at Harvard Medical School,[1][2][3] and Director of the Harvard Gene Therapy Initiative.[4]

He is a Director of Enzon Pharmaceuticals, Inc.,[5] and Biogen Idec, Inc..[6]



  • Lindemann, D., Patriquin, E., Feng, S. and Mulligan, R.C. 1997 "Versatile retovirus vector systems for regulated gene expression in vitro and in vivo". Molecular Medicine 3:466-476.
  • Goodell, M.A., Rosenzweig, H-.K., Marks, D.G., DeMaria, M., Paradis, G., Grupp, S.A., Sieff, C.A., Mulligan, R.C. and Johnson, R.P. 1997. "Dye efflux studies suggest the existence of CD34-negative/low hematopoietic stem cells in multiple species". Nature Medicine 3:1337–1345.
  • Mach, N., Lantz, C.S., Galli, S.J., Reznikoff, G., Mihm, M., Small, C., Granstein, R., Beissert, S., Sadelain, M., Mulligan, R.C. and Dranoff, G. 1998. "Involvement of interleukin-3 in delayed-type hypersensitivity". Blood 92:778-783.


  1. ^ "Richard C. Mulligan, Ph.D. | HMS Department of Genetics". Retrieved 2016-06-21. 
  2. ^
  3. ^ "Richard C. Mulligan, Ph.D. - DF/HCC". Retrieved 2016-06-21. 
  4. ^ "Richard C. Mulligan". Archived from the original on August 4, 2011. Retrieved 2016-06-21. 
  5. ^ "Enzon". Retrieved 2016-06-21. 
  6. ^ "Business Briefing / Biotechnology - latimes". Retrieved 2016-06-21. 
  7. ^ "Searle Scholars Program : Richard C. Mulligan (1983)". Retrieved 2016-06-21. 

External links[edit]